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sUmmARY – Hormone replacement therapy is mandatory to maintain quality of life and bone 
mineralization status in patients with gonadal dysgenesis. occasionally, these patients need higher 
than recommended estrogen dosage to prevent signs and symptoms of hypoestrogenic state. our 
18-year-old female patient with xY sex reversal syndrome was gonadectomized and administered 
conventional hormone replacement therapy. Gonadoblastoma was found in the excised streak go-
nad. Five years after continuous replacement therapy, the patient reported unexpectedly hot flushes 
and amenorrhea in spite of regular hormone intake. severe osteopenia was also detected. Uncon-
ventionally high estrogen dose was given with additional daily vitamin d and calcium supplement. 
dual energy x-ray absorptiometry revealed lesser but evident osteopenia and the patient reported 
repeated bleeding without hot flushes on the new hormone regimen. individualized dosage of estro-
gen is essential for these patients according to their bone status and subjective symptoms. early 
therapy initiation along with continuous and frequent evaluation of bone status and quality of life 
is advised.
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Introduction
The xY sex reversal syndrome, also called xY go-
nadal dysgenesis or swyer syndrome, is a condition in 
which individuals with 46 xY karyotype in each cell 
have a female appearance. people with this disorder 
have female external genitalia and normal uterus and 
fallopian tubes. However, they do not have functional 
gonads (ovaries or testes). instead, they have undevel-
oped gonadal tissue called streak gonads. only 20% 
of all 46 xY pure gonadal dysgenesis are explained by 
a mutation or a deletion in sRY1. variations of phe-
notypical appearance in these patients are described 
in the literature with or without evident background 
of the causing factor. diagnostic procedure is well es-
tablished and after confirmation of the syndrome hor-
mone replacement therapy (HRt) is essential because 
of no gonadal estrogenic production. it is important to 
induce development of the breasts, the existing mul-
lerian structures, inducing menstrual bleeding as well 
as reducing the risk of decrease in bone mineral den-
sity. Continuous therapy is advised to avoid estrogen 
withdrawal symptoms and negative effects on the life 
quality. The sooner the therapy begins the greater are 
the benefits for the patient. The incidence of gonad 
malignancy development in patients with gonadal 
dysgenesis is high, approximately 25%-30%1. The most 
common gonadal tumors in swyer syndrome patients 
are gonadoblastoma and dysgerminoma. Therefore, 
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laparoscopic gonadectomy is highly recommended as 
a standard prophylactic procedure. Although rarely 
reported in xY female patients, urinary tract anoma-
lies are possible1.
Case Report
We present a case of a young woman with sw-
yer syndrome after laparoscopic gonadectomy, who 
encountered several subjective and clinical difficul-
ties after five years of continuous hormonal treat-
ment. she got her menarche at the age of 15 and once 
a year had scant bleeding. The patient first visited 
her gynecologist at the age of 17 as she complained 
of cycle irregularities. progesterone therapy induced 
light vaginal bleeding twice. At the age of 18, she 
visited our department because menstrual bleeding 
did not follow regular pattern as she was instructed. 
in the meantime, the patient developed hot flushes. 
The patient was 178 cm high, of athletic built, body 
weight 70 kg (body mass index (Bmi) 22.1). she had 
developed breasts (tanner 2/3), axillary and pubic 
hair (tanner 3). Her external genitals were normally 
developed and virgo. Gonadotropin values were high 
(FsH 48.8 iU/l, lH 18.8 iU/l), estrogens were low 
(e2 0.05 nmol/l), HCG was negative, and the rest 
of hormonal laboratory findings were within the nor-
mal range. transabdominal ultrasound showed small 
uterus (30x20 mm), a solid structure like ovarian tis-
sue on the right side (1.8x1 cm) with no detectable 
ovarian tissue on the left side. Cytogenetic analysis 
showed 46 xY karyotype and positive sRY region 
on Y chromosome without mutations (pCR, FisH). 
After primary evaluation, the patient was informed 
and guided for the following procedures. The patient 
accepted psychological counseling started and contin-
ued during evaluation of her diagnosis at our hospital. 
sequential HRt was prescribed immediately at the 
age of 18 (2 mg estradiol/1 mg norethisterone ace-
tate; trisequens®, novo nordisk), which eliminated 
hot flushes and induced regular menstrual bleedings. 
several months later during diagnostic laparoscopy, a 
small uterus with both tubes and both streak gonads 
was visualized; biopsy showed connective tissue and 
ovarian stroma without follicles. vaginal examina-
tion performed before the operation (the patient in-
formed us that in the meantime she had been sexu-
ally active without any interference) revealed normal 
vagina and small cervix. laparoscopic gonadectomy 
was performed with the patient’s informed consent. 
most parts of the gonadal streaks were firm connec-
tive tissue found between discrete areas of ovarian 
stroma, with rare and microscopically small inclusion 
cysts and psammoma bodies. There were no primary 
follicles. in the left gonadal streak, an accidental tu-
mor was found, measuring 2 mm in diameter (Fig. 1a, 
b). tumor nests were found to immunohistochemi-
cally stain positive for plAp, Cd117 and s-100, and 
Fig. 1. Gonadoblastoma: (a) the tumor consisting of germ 
cells and sex cord derivatives in cellular nests surrounded 
by connective tissue stroma (HE, X100); (b) coronal pat-
tern of sex cord derivatives along the periphery of the nests 
and surrounding small nests containing hyaline material; 
in-between, a mixture of cells (HE, X400).
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negative for CeA, GFAp, desmin and CK mnF16 
(Fig. 2a-c). According to morphological and immu-
nohistochemical findings, the diagnosis of gonado-
blastoma was made. The right gonadal streak showed 
no signs of tumor in ovarian and fibrous connective 
stroma. intravenous urography showed no malforma-
tions of the urinary tract. Five years later, in spite of 
continuous hormonal therapy, hot flushes and amen-
orrhea developed. vaginal ultrasound showed thin 
one-layered endometrium. The patient was eager to 
have regular bleeding. Additional laboratory endo-
crinological analysis revealed no other causes of this 
state. on thorough evaluation bone mineral density 
was evaluated as well. severe osteopenia was detected 
and diagnosed by dexA. Her hip neck t score was 
-1.64 and Z score -1.62, whereas lumbar spine t score 
was -2.45 and Z score -2.34. Commercially available 
monthly oral sequential combined estrogen-proges-
terone preparations were changed a few times for dif-
ferent progestins or different estrogen doses, without 
any impact on hot flushes or endometrial thickness 
until the three-month regimen of 3 mg estradiol (es-
trofem®, novo nordisk) daily was introduced, op-
posed with 10 mg dydrogesterone (dabroston®, Be-
lupo) for the last 14 days. Furthermore, the patient 
was administered vitamin d (800 iU) and calcium 
(1000-1500 mg) daily. After a year of this therapy, os-
teopenia was less severe; hip neck t score was 1.6 and 
Z score -1.5, whereas lumbar spine t score was -2.1 
and Z score -2.0. later on, we reduced the estradiol 
daily dose to 2 mg and added gestagen every other 
month. The patient bled regularly and she was satis-
fied with her therapy and quality of life. two years 
later, in the course of her check-up at our hospital, 
the patient reported scant but regular bleeding pat-
terns without hot flushes. transvaginal ultrasound 
scan showed unchanged uterus size (29x20x20 mm) 
with endometrium that was never thicker than 3 mm 
Fig. 2. Immunohistochemistry of the gonadoblastoma: (a) 
strong cytoplasmic reaction for PLAP was observed in tu-
mor cells; (b) strong cytoplasmic and membrane reaction 
for CD117 was observed in tumor cells; (c) reaction for 
S-100 was found in tumor cell cytoplasm (X400).
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in proliferative phase. Bone mineral density did not 
change. osteopenia was still present with hip neck t 
score 1.8 and Z score -1.77, and lumbar spine t score 
-2.24 and Z score -2.17.
Discussion
The explanation for the developed breasts, spon-
taneous spotting and good early response to gestagen 
therapy in the patient’s pubertal age is that there must 
have been some hormonal production by either some 
ovarian/gonadal tissue which degenerated prema-
turely or by peripheral conversion of androgens2. The 
patient experienced the first hot flushes in her teenage 
years, which are expected in patients with pure go-
nadal dysgenesis. Hot flushes were blocked by contin-
uous sequential HRt, starting at age 18. The finding 
of unilateral gonadoblastoma on the surgery justified 
the procedure of gonadectomy.
Young women who develop symptoms of estrogen 
deficiency also lose bone3. The extent of bone loss in 
these women is directly proportional to the length of 
time without therapy4. Bone mineral density increases 
under estrogen influence beginning in the peripuber-
tal period until around age 305. dual energy x-ray 
absorptiometry (dexA) or bone densitometry is the 
standard method to measure bone mineral density. 
The spine and hip are usually measured. The World 
Health organization established the criteria for de-
termining t-score and Z-score. in our patient, os-
teopenia of lumbar spine and hip bone developed in 
spite of continuous HRt, suggesting her to be at a 
greater risk of fracture than young women of her age5. 
Bone mineral density (expressed as Z-score) of the 
spine was -2.34 and of the hip -1.62. early teenage 
period is the time when the bulk of bone tissue is laid 
down under the influence of peak estrogen production 
and this development cannot be easily compensated 
later6,7. We believe that our patient started with HRt 
too late.
later in life, the patient once again developed the 
signs of relative estrogen deficiency manifested as 
clinical signs and symptoms in spite of therapy. There-
fore, at that time the patient needed greater exogenous 
dose of estrogen to stop hot flushes, to maintain en-
dometrial proliferation and to enable bleedings. Her 
uterus size throughout the time of continuous therapy 
did not enlarge and stayed hypoplastic. We can only 
presume that the tissue sensitivity for exogenous es-
trogens might be lower in our patient8. sudden ap-
pearance of hot flushes as well as severe osteopenia 
could be caused by the fact that the patient lost weight 
(8 kg) deliberately and decreased her Bmi of 22 to 19, 
which is a reported and known risk factor for osteope-
nia9. Furthermore, resistant osteopenia in this case 
may also be the result of relative androgen deficiency, 
which can also compromise bone mineral density10.
Conclusion
We found extremely important to ensure young 
xY reversal syndrome patients with additional psy-
chological treatment to help them in developing 
self-esteem, sexuality and reaching right decisions 
during treatment. psychological support ensured an 
enormous positive impact to our patient and helped 
her understand all suggested diagnostic, surgical and 
other medication treatments. An individualized ther-
apeutic approach is mandatory in order to maintain 
their well-being, quality of life, and appropriate bone 
mineralization status11. sometimes it is worthwhile 
to introduce higher than standard doses of estrogens, 
with vitamin d and calcium supplements. it is advis-
able to make more frequent search for symptoms of 
estrogen deprivation, as well as frequent check-ups of 
bone mineral loss. in our experience, there is a serious 
lack of relevant literature about resistance of this par-
ticular group of patients to conventional estrogen dose 
in replacement therapy. We did not find any literature 
data on bone mineral density in younger patients.
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sažetak
neoČeKivAni isHod Kod liJeČene BolesniCe s GonAdnom disGeneZom
V. Fenzl, Ž. Duić, J. Popić-Ramač i A. Škrtić
U bolesnica s disgenezom gonada liječenje hormonskom nadomjesnom terapijom potrebno je kako bi se očuvala kvali-
teta života te primjerena mineralizacija koštanog tkiva. U liječenju je ponekad potrebno primijeniti višu dozu estrogena od 
preporučene kako bi se spriječili znaci i simptomi hipoestrogenemije. prikazuje se osamnaestgodišnja bolesnica s čistom 
disgenezom gonada, liječena standardnom hormonskom nadomjesnom terapijom u koje je učinjena gonadektomija. Unutar 
fibrotičnog gonadnog tračka nađen je gonadoblastom. Bolesnica je liječena kontinuiranom hormonskom nadomjesnom 
terapijom pet godina, nakon čega je naglo razvila amenoreju te valove vrućine. denzitometrijom se dokazala teška osteo-
penija. Bolesnica je potom liječena visokim dozama estrogena uz dodatak vitamina d i kalcija svakodnevno. denzitome-
trijom se i dalje verificirala postojana osteopenija, ali manje izražena. Uspostavljena su redovita krvarenja bez valova vru-
ćine tek uz tromjesečni režim hormonske terapije (estradiol 3 mg/3 mjeseca i didrogesteron 10 mg/posljednjih 14 dana). U 
bolesnica s čistom disgenezom gonada uputno je rano započeti s hormonskim liječenjem uza stalne i česte kontrole statusa 
koštanog tkiva i kvalitete života. nužan je individualni pristup hormonskom nadomjesnom liječenju ovisno o subjektivnim 
smetnjama i statusu koštanog tkiva.
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